Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial
Titel:
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial
Auteur:
Luger, Selina M. Wang, Victoria X. Rowe, Jacob M. Litzow, Mark R. Paietta, Elisabeth Ketterling, Rhett P. Lazarus, Hillard Rybka, Witold B. Craig, Michael D. Karp, Judith Cooper, Brenda W. Makary, Adel Z. Kaminer, Lynne S. Appelbaum, Frederick R. Larson, Richard A. Tallman, Martin S.